Results 241 to 250 of about 478,311 (305)

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

open access: yesArthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli   +4 more
wiley   +1 more source

Vascular etiologies of unilateral pulmonary fibrosis: Case series and literature overview. [PDF]

open access: yesRadiol Case Rep
Cozzi D   +7 more
europepmc   +1 more source

Pulmonary vascular disease

Current Opinion in Pulmonary Medicine, 2001
This review article discusses three topics related to pulmonary vascular disease: 1) pulmonary vascular changes associated with portal hypertension, 2) ANCA-associated pulmonary vasculitis, and 3) Takayasu's arteritis. Hepatopulmonary syndrome and pulmonary hypertension have recently been reported as pulmonary vascular changes accompanied with portal ...
G F, Pineo, R D, Hull
openaire   +7 more sources

Pulmonary Vascular Diseases

Comprehensive Physiology, 2011
AbstractDiseases of the pulmonary vasculature are a cause of increased pulmonary vascular resistance (PVR) in pulmonary embolism, chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary arterial hypertension or decreased PVR in pulmonary arteriovenous malformations on hereditary hemorrhagic telangiectasia, portal hypertension, or ...
Melot, Christian, Naeije, Robert
openaire   +2 more sources

Home - About - Disclaimer - Privacy